We have been informed by the company, Janssen, that it has decided to withdraw its marketing authorisation application for sirukumab. Consequently, we have suspended this appraisal.
 
Status Suspended
Process STA
ID number 1002

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Janssen (sirukumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Arthritis Action
  National Rheumatoid Arthritis Society
Professional groups British Society for Rheumatology
  Primary Care Rheumatology Society
  Royal College of Physicians
  UK Clinical Pharmacy Association

Commentators

Comparator companies AbbVie
  Accord Healthcare - (CAU not returned, not participating)
  Amdipharm Mercury - (CAU not returned, not participating)
  Biogen
  Bristol-Myers Squibb
  Concordia international - (CAU not returned, not participating)
  Eli Lilly
  Hameln pharmaceuticals - (CAU not returned, not participating)
  Hospira - (CAU not returned, not participating)
  medac - (CAU not returned, not participating)
  Merck Sharp & Dohme
  Napp
  Nordic Pharma - (CAU not returned, not participating)
  Orion Pharma - (CAU not returned, not participating)
  Pfizer
  Roche
  Rosemont Pharmaceuticals - (CAU not returned, not participating)
  Sandoz - (CAU not returned, not participating)
  UCB Pharma Limited
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
30 October 2017 Suspended, We have been informed by the company, Janssen, that it has decided to withdraw its marketing authorisation application for sirukumab. Consequently, we have suspended this appraisal.
28 July 2017 Invitation to participate
25 April 2017 Referral
21 April 2017 In progress, Topic referred
03 January 2017 - 31 January 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance